Given CELSR2 is a transmembrane receptor, and our study advised that CELSR2 abundance is inversely associated with plasma LDL-C level and can protect against CAD, activating CELSR2 could hold promise for treating dyslipidaemia and CAD. The gene discussed is CELSR2; the disease is coronary artery disorder.